Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood
Infectious diseases such as coronavirus disease 2019 (COVID-19) continue to pose significant global health challenges. Effective management of reinfection risks depends on sustained levels of binding and neutralizing antibodies. However, conventional methods—such as enzyme-linked immunosorbent assay...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | hLife |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949928325000343 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850110205410410496 |
|---|---|
| author | Xiaotian Tan Yujuan Chai Ruihan Li Binmao Zhang Hao Li Jie Zhang Tianen Zhu Weishu Wu Lixiang An Shi Hu Bin Yang Li Wang Zhenqiu Cao Hongjiu Zhang Peng Wang Lingling Yu Shan Yin Xingyu Li Fei Shao Jianheng Huang Jinze Li Fan Yang Chao Zhao Jiajia Guo Lin Zeng Dong Liang Zhengting Zou Hairong Zheng Xudong Fan Liangzhi Xie Yunlong Cao Hui Yang |
| author_facet | Xiaotian Tan Yujuan Chai Ruihan Li Binmao Zhang Hao Li Jie Zhang Tianen Zhu Weishu Wu Lixiang An Shi Hu Bin Yang Li Wang Zhenqiu Cao Hongjiu Zhang Peng Wang Lingling Yu Shan Yin Xingyu Li Fei Shao Jianheng Huang Jinze Li Fan Yang Chao Zhao Jiajia Guo Lin Zeng Dong Liang Zhengting Zou Hairong Zheng Xudong Fan Liangzhi Xie Yunlong Cao Hui Yang |
| author_sort | Xiaotian Tan |
| collection | DOAJ |
| description | Infectious diseases such as coronavirus disease 2019 (COVID-19) continue to pose significant global health challenges. Effective management of reinfection risks depends on sustained levels of binding and neutralizing antibodies. However, conventional methods—such as enzyme-linked immunosorbent assays (ELISA) and virus neutralization tests (VNT)—are limited by complex workflows, long assay durations, and high sample volume requirements, making them less suitable for routine, decentralized, or time-sensitive surveillance. This study presents a custom-developed tip optofluidic immunoassay (TOI) platform that enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood. The system integrates batch-fabricated microfluidic immunoreactors with a portable chemiluminescent imaging station, completing both binding and neutralization capability assessments within 40 min. TOI achieves a broad dynamic range (3–4 orders of magnitude), high signal-to-noise ratio (∼10,000), and excellent sensitivity for immunoglobulin G (IgG) detection. A renovated version of the rapid in vitro inhibition assay (RIVIA) is incorporated to evaluate neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with greater speed and cost-efficiency. In clinical studies, TOI successfully quantified antibody protection against multiple variants, identifying individuals with broad-spectrum immunity to both wild-type and XBB strains. With its high-precision, rapid turnaround, and minimal sample requirement, TOI offers a valuable tool for decentralized immune surveillance and personalized immunization strategy development. |
| format | Article |
| id | doaj-art-99a5677732cd43d08c7e5a5149948c08 |
| institution | OA Journals |
| issn | 2949-9283 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | hLife |
| spelling | doaj-art-99a5677732cd43d08c7e5a5149948c082025-08-20T02:37:52ZengElsevierhLife2949-92832025-07-013733835610.1016/j.hlife.2025.04.005Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip bloodXiaotian Tan0Yujuan Chai1Ruihan Li2Binmao Zhang3Hao Li4Jie Zhang5Tianen Zhu6Weishu Wu7Lixiang An8Shi Hu9Bin Yang10Li Wang11Zhenqiu Cao12Hongjiu Zhang13Peng Wang14Lingling Yu15Shan Yin16Xingyu Li17Fei Shao18Jianheng Huang19Jinze Li20Fan Yang21Chao Zhao22Jiajia Guo23Lin Zeng24Dong Liang25Zhengting Zou26Hairong Zheng27Xudong Fan28Liangzhi Xie29Yunlong Cao30Hui Yang31Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; State Key Laboratory of Biomedical Imaging Science and System, Guangdong, China; Correspondence:Department of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Guangdong, China; Correspondence:Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; State Key Laboratory of Biomedical Imaging Science and System, Guangdong, ChinaInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; Department of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Guangdong, ChinaInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; National Innovation Center for Advanced Medical Devices, Guangdong, ChinaBeijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing, ChinaEmergency Department, Shenzhen University General Hospital, Shenzhen University, Guangdong, ChinaDepartment of Biomedical Engineering, University of Michigan, Michigan, USANational Innovation Center for Advanced Medical Devices, Guangdong, ChinaInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; State Key Laboratory of Biomedical Imaging Science and System, Guangdong, China; University of Chinese Academy of Sciences, Beijing, ChinaBeijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing, ChinaBeijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing, ChinaInstitute of Zoology, Chinese Academy of Sciences, Beijing, ChinaInstitute of Zoology, Chinese Academy of Sciences, Beijing, ChinaChangping Laboratory, Beijing, ChinaChangping Laboratory, Beijing, ChinaChangping Laboratory, Beijing, ChinaChangping Laboratory, Beijing, ChinaChangping Laboratory, Beijing, ChinaInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; Department of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Guangdong, ChinaInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, ChinaState Key Laboratory of Biomedical Imaging Science and System, Guangdong, China; Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, ChinaInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; State Key Laboratory of Biomedical Imaging Science and System, Guangdong, ChinaInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; State Key Laboratory of Biomedical Imaging Science and System, Guangdong, ChinaInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; State Key Laboratory of Biomedical Imaging Science and System, Guangdong, ChinaInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; State Key Laboratory of Biomedical Imaging Science and System, Guangdong, ChinaInstitute of Zoology, Chinese Academy of Sciences, Beijing, ChinaInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; State Key Laboratory of Biomedical Imaging Science and System, Guangdong, China; Correspondence:Department of Biomedical Engineering, University of Michigan, Michigan, USA; Correspondence:Beijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing, China; Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China; Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Correspondence:Changping Laboratory, Beijing, China; BIOPIC, Peking University, Beijing, China; Correspondence:Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China; State Key Laboratory of Biomedical Imaging Science and System, Guangdong, China; Correspondence:Infectious diseases such as coronavirus disease 2019 (COVID-19) continue to pose significant global health challenges. Effective management of reinfection risks depends on sustained levels of binding and neutralizing antibodies. However, conventional methods—such as enzyme-linked immunosorbent assays (ELISA) and virus neutralization tests (VNT)—are limited by complex workflows, long assay durations, and high sample volume requirements, making them less suitable for routine, decentralized, or time-sensitive surveillance. This study presents a custom-developed tip optofluidic immunoassay (TOI) platform that enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood. The system integrates batch-fabricated microfluidic immunoreactors with a portable chemiluminescent imaging station, completing both binding and neutralization capability assessments within 40 min. TOI achieves a broad dynamic range (3–4 orders of magnitude), high signal-to-noise ratio (∼10,000), and excellent sensitivity for immunoglobulin G (IgG) detection. A renovated version of the rapid in vitro inhibition assay (RIVIA) is incorporated to evaluate neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with greater speed and cost-efficiency. In clinical studies, TOI successfully quantified antibody protection against multiple variants, identifying individuals with broad-spectrum immunity to both wild-type and XBB strains. With its high-precision, rapid turnaround, and minimal sample requirement, TOI offers a valuable tool for decentralized immune surveillance and personalized immunization strategy development.http://www.sciencedirect.com/science/article/pii/S2949928325000343fingertip bloodoptofluidic immunoassayantibody protection assessmentcoronavirus disease 2019 (COVID-19)biosensing |
| spellingShingle | Xiaotian Tan Yujuan Chai Ruihan Li Binmao Zhang Hao Li Jie Zhang Tianen Zhu Weishu Wu Lixiang An Shi Hu Bin Yang Li Wang Zhenqiu Cao Hongjiu Zhang Peng Wang Lingling Yu Shan Yin Xingyu Li Fei Shao Jianheng Huang Jinze Li Fan Yang Chao Zhao Jiajia Guo Lin Zeng Dong Liang Zhengting Zou Hairong Zheng Xudong Fan Liangzhi Xie Yunlong Cao Hui Yang Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood hLife fingertip blood optofluidic immunoassay antibody protection assessment coronavirus disease 2019 (COVID-19) biosensing |
| title | Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood |
| title_full | Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood |
| title_fullStr | Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood |
| title_full_unstemmed | Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood |
| title_short | Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood |
| title_sort | tip optofluidic immunoassay evaluating covid 19 antibody protection with 1 μl fingertip blood |
| topic | fingertip blood optofluidic immunoassay antibody protection assessment coronavirus disease 2019 (COVID-19) biosensing |
| url | http://www.sciencedirect.com/science/article/pii/S2949928325000343 |
| work_keys_str_mv | AT xiaotiantan tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT yujuanchai tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT ruihanli tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT binmaozhang tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT haoli tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT jiezhang tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT tianenzhu tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT weishuwu tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT lixiangan tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT shihu tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT binyang tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT liwang tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT zhenqiucao tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT hongjiuzhang tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT pengwang tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT linglingyu tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT shanyin tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT xingyuli tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT feishao tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT jianhenghuang tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT jinzeli tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT fanyang tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT chaozhao tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT jiajiaguo tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT linzeng tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT dongliang tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT zhengtingzou tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT hairongzheng tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT xudongfan tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT liangzhixie tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT yunlongcao tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood AT huiyang tipoptofluidicimmunoassayevaluatingcovid19antibodyprotectionwith1mlfingertipblood |